Biobot Surgical Pte. Ltd aims to be a global technology leader in minimally invasive robotic-assisted surgery. Through collaborative partnership with Singapore General Hospital (SGH) in years of clinical trials, the iSRobotTM Mona Lisa robotic transperineal biopsy device (rTPB) has evolved into a high performance product which enables surgeons to accurately and reliably extract prostate biopsy tissues through 2 small needle puncture incisions on the perineal skin.

The original prototype named BioXbot was first developed in 2001 under the partnership between the late Prof. Ng Wan Sing of Nanyang Technological University (NTU) and Prof. Christopher Cheng of (SGH), under the Singapore Health Services Pte Ltds (Singhealth) cluster. The iSRobot Mona Lisa has evolved into the latest state-of-the-art new generation design developed jointly by Prof C Cheng, Drs John Yuen and Henry Ho and the Biobots team. Patent shared jointly between NTU/Singhealth and Biobot is pending.

Our Technology Enhance The Surgeons Capability
Biobot Surgical Pte. Ltd has licensed the technology from NTU/SingHealth to commercialise the surgical robot. The iSRobotTM Mona Lisa had clinically proven the technologys capability to double the detection rate of prostate cancer as compared with the traditional TRUS procedure.

As of 2014, the device has gone through clinical trials with more than 600 patients. The excellent patient clinical outcome over the last 2 years have prompted the company to explore application of the robot beyond rTPB, in the areas of focal biopsy, and focal therapy applications. The iSRobotTM Mona Lisa has an optional MRI-Ultrasound fusion capability that enables targeted biopsies and potentially targeted treatment.